Kamari Pharma is a biopharmaceutical company aiming to develop and commercialize proprietary small molecule inhibitors of TRPV3, a cation channel expressed primary in keratinocytes, for the treatment of dermatological conditions with unmet need. TRPV3 has been extensively evaluated as a target for drug development, identified as the cause of Olmsted syndrome in humans, and shows involvement in various skin disorders including keratoderma, atopic dermatitis, psoriasis, rosacea, and post-burn pruritus.